Translational Neurodegeneration, Год журнала: 2023, Номер 12(1)
Опубликована: Янв. 26, 2023
Alzheimer's disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined activators (CMA) the AD rat model and observed that CMA improves AD-associated histological parameters in animals. promotes mitochondrial fatty acid uptake from cytosol, facilitates oxidation mitochondria, alleviates oxidative stress.
Язык: Английский
The Lancet, Год журнала: 2021, Номер 397(10284), С. 1577 - 1590
Опубликована: Март 2, 2021
Язык: Английский
Процитировано
3009
Molecules, Год журнала: 2020, Номер 25(24), С. 5789 - 5789
Опубликована: Дек. 8, 2020
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in brain and it main cause dementia, which characterized by decline thinking independence personal daily activities. AD considered multifactorial disease: two hypotheses were proposed as for AD, cholinergic amyloid hypotheses. Additionally, several risk factors such increasing age, genetic factors, head injuries, vascular diseases, infections, environmental play role disease. Currently, there are only classes approved drugs to treat including inhibitors cholinesterase enzyme antagonists N-methyl d-aspartate (NMDA), effective treating symptoms but do not cure or prevent Nowadays, research focusing on understanding pathology targeting mechanisms, abnormal tau protein metabolism, β-amyloid, inflammatory response, free radical damage, aiming develop successful treatments capable stopping modifying course AD. This review discusses currently available future theories development new therapies disease-modifying therapeutics (DMT), chaperones, natural compounds.
Язык: Английский
Процитировано
1824
Alzheimer s & Dementia Translational Research & Clinical Interventions, Год журнала: 2022, Номер 8(1)
Опубликована: Янв. 1, 2022
Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow progression, improve cognition, and reduce behavioral disturbances of AD. We review current clinical trials drugs in development for treatment
Язык: Английский
Процитировано
535
Alzheimer s & Dementia Translational Research & Clinical Interventions, Год журнала: 2020, Номер 6(1)
Опубликована: Янв. 1, 2020
Abstract Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions dollars annually. We review the pipeline drugs biologics in clinical trials for treatment AD. use Common Related Dementias Research Ontology (CADRO) to classify targets mechanisms action. our annual reports past 5 years provide longitudinal insight into drug development Methods reviewed ClinicalTrials.gov as February 27, 2020, identified all pharmacologic agents currently being developed AD represented on this widely used U.S. Food Drug Administration registry. Results There are 121 Twenty‐nine 36 Phase 3 trials, 65 73 2 27 1 trials. Twelve target cognitive enhancement 12 intended treat neuropsychiatric behavioral symptoms. 97 modification Compared 2019 pipeline, there an increase number disease‐modifying targeting pathways other than amyloid or tau. Discussion The 2020 has innovations that hope greater success programs. Review over show progressive emphasis non‐amyloid targets, including candidate treatments inflammation, synapse neuronal protection, vascular factors, neurogenesis, epigenetic interventions. been marked growth repurposed pipeline. image
Язык: Английский
Процитировано
498
Alzheimer s & Dementia Translational Research & Clinical Interventions, Год журнала: 2021, Номер 7(1)
Опубликована: Янв. 1, 2021
Abstract Introduction The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline drugs in clinical trials for treatment AD. Methods interrogated ClinicalTrials.gov, federal registry to identify trials. Results There 126 agents 152 assessing new therapies AD: 28 Phase 3 trials, 74 2, and 24 1. majority (82.5%) target underlying biology AD intent modification; 10.3% putative cognitive enhancing agents; 7.1% being developed reduce neuropsychiatric symptoms. Discussion This analysis shows that biological processes more diversified, biomarkers regularly used, repurposed explored determine their utility
Язык: Английский
Процитировано
418
The Journal of Prevention of Alzheimer s Disease, Год журнала: 2021, Номер unknown, С. 1 - 16
Опубликована: Янв. 1, 2021
Alzheimer’s disease is a progressive, irreversible neurodegenerative impacting cognition, function, and behavior. progresses along continuum from preclinical disease, to mild cognitive and/or behavioral impairment then dementia. Recently, clinicians have been encouraged diagnose earlier, before patients progressed The early accurate detection of disease-associated symptoms underlying pathology by fundamental for the screening, diagnosis, subsequent management patients. It also enables their caregivers plan future make appropriate lifestyle changes that could help maintain quality life longer. Unfortunately, detecting early-stage in clinical practice can be challenging hindered several barriers including constraints on clinicians’ time, difficulty accurately diagnosing pathology, healthcare providers often dismiss as part normal aging process. As prevalence this continues grow, current model diagnosis patient will need evolve integrate care across disciplines continuum, beginning with primary care. This review summarizes importance establishing an related practical ‘how-to’ guidance considerations, tools used throughout diagnostic journey.
Язык: Английский
Процитировано
387
Nature reviews. Neuroscience, Год журнала: 2021, Номер 23(1), С. 53 - 66
Опубликована: Ноя. 23, 2021
Язык: Английский
Процитировано
328
Translational Neurodegeneration, Год журнала: 2022, Номер 11(1)
Опубликована: Янв. 28, 2022
Abstract Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that known to arise as the progresses. A growing body evidence suggests pathological alterations neuronal circuits and synapses may provide mechanistic link between amyloid β (Aβ) tau pathology thus serve an obligatory relay cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play important role maintaining synaptic plasticity learning memory. Considering AD disorder, BDNF has attracted increasing attention potential diagnostic biomarker therapeutical molecule for Although depletion been linked with Aβ accumulation, phosphorylation, neuroinflammation apoptosis, exact mechanisms underlying effect impaired signaling on still unknown. Here, we present overview how genomic structure is connected regulate signaling. We then discuss BDNF-targeting therapeutics
Язык: Английский
Процитировано
327
Alzheimer s & Dementia Translational Research & Clinical Interventions, Год журнала: 2023, Номер 9(2)
Опубликована: Апрель 1, 2023
Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.
Язык: Английский
Процитировано
325
Ageing Research Reviews, Год журнала: 2021, Номер 72, С. 101464 - 101464
Опубликована: Сен. 20, 2021
Alzheimer's disease (AD) is a complex neurodegenerative in the elderly and most common cause of human dementia. AD characterized by accumulation abnormal protein aggregates including amyloid plaques (composed beta-amyloid (Aβ) peptides) neurofibrillary tangles (formed hyper-phosphorylated tau protein). Synaptic plasticity, neuroinflammation, calcium signaling etc. also show dysfunction patients. Autophagy an evolutionarily conserved lysosome-dependent cellular event eukaryotes. It closely linked to modulation metabolism, through which damaged organelles mis-folded proteins are degraded then recycled maintain homeostasis. Accumulating evidence has shown that impaired autophagy contributes pathogenesis. In present review, we highlight role autophagy, bulk selective regulating metabolic circuits We discuss potential future perspectives autophagy-inducing strategies therapeutics.
Язык: Английский
Процитировано
223